Promise and pitfalls of administrative data in evaluating pregnancy outcomes

Pharmacoepidemiology and Drug Safety

Volumn 16, Issue 11, 2007, Pages 1181-1183

  Andrews, Elizabeth B ^a   Tennis, Patricia ^a  

^a RTI HEALTH SOLUTIONS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

BIRTH DEFECT; CARDIOVASCULAR MALFORMATION; DISEASE ASSOCIATION; DRUG SAFETY; FIRST TRIMESTER PREGNANCY; HUMAN; INFORMATION RETRIEVAL; LOGISTIC REGRESSION ANALYSIS; MEDICAL RECORD REVIEW; MONOTHERAPY; NOTE; PHARMACOEPIDEMIOLOGY; PREGNANCY OUTCOME; PREMATURITY; PRENATAL DRUG EXPOSURE; PREVALENCE; PRIORITY JOURNAL; TERATOGENICITY; THIRD TRIMESTER PREGNANCY;

ABNORMALITIES, DRUG-INDUCED; ANTIDEPRESSIVE AGENTS; DATA COLLECTION; DATABASES, FACTUAL; FEMALE; HUMANS; PHARMACOEPIDEMIOLOGY; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; RISK;

EID: 36249002225     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1499     Document Type: Note

References (5)

1. Cole JA, Ephross SA, Cosmatos IS, Walker AM. Paroxetine in the first trimester and the prevalence of congenital malfor- mations. Pharmacoepidemiol Drug Saf. 2007; 16: 1075-1085.
2. Cole JA, Modell JG, Haight BR, Cosmotos IS, Stoler JM, Walker AM. Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007; 16: 474-484.
3. Davis RL, Rubanowice D, McPhillips H, et al. For the HMO research network center for education and research in thera- peutics. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemioi Drug Saf 2007; 16: 1086-1094.
4. Louik C, Lin AE, Werler MM, Hernández-Díaz S, Mitchell AA. M.D first-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007; 356: 2675-2683.
5. U.S. Department of Health and Human Services Food and Drug Administration. Guidance for Industry Establishing Pregnancy Exposure Registries. August 2002. http://www.fda.gov/cder/guidance/index.htm. Accessed August 13, 2007.